Question 22

Mycophenolate is subject to a Risk Evaluation and Mitigation Strategy (REMS) program because current patients should avoid becoming pregnant.

Mycophenolate is a medication that is associated with significant risks during pregnancy and, as such, is subject to a REMS program to ensure that patients are aware of these risks and take necessary precautions to avoid pregnancy while undergoing treatment.

A) Sertraline

Sertraline is an antidepressant that is not specifically associated with a REMS program related to pregnancy risks. Although it can be used during pregnancy, the potential risks are not deemed significant enough to require a REMS, making it less relevant to the question.

B) Ondansetron

Ondansetron, an antiemetic, does not have a REMS program related to pregnancy. While it is important to consider its usage during pregnancy, it does not carry the same severe implications as medications that require a REMS due to potential fetal harm, thus it is not the correct answer.

C) Montelukast

Montelukast, a medication for asthma and allergies, does not have a REMS program associated with pregnancy risks. Its use in pregnancy is not as highly restricted as that of mycophenolate, making it an incorrect option in this context.

D) Mycophenolate

Mycophenolate is a medication that poses serious risks of teratogenic effects if taken during pregnancy. To mitigate these risks, it is included in a REMS program that emphasizes the importance of avoiding pregnancy during treatment, making it the correct answer to the question.

Conclusion

Mycophenolate is the only medication listed that has a REMS program specifically aimed at preventing pregnancy due to its significant risks. The other options—sertraline, ondansetron, and montelukast—do not have comparable concerns that necessitate such a program, solidifying mycophenolate as the definitive answer.